home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Safety and efficacy of Nutriterra confirmed - Novel plant-based source of total omega-3 significantly improves blood profiles in human clinical trial


USA
March 3, 2021

Nuseed Nutritional US Inc., has completed a human clinical trial, confirming the safety and efficacy of Nutriterra® as a novel plant-based source of total omega-3 nutrition.

Results from the trial indicated patients taking Nutriterra® Total Omega-3 dietary supplements readily absorbed the oil’s long-chain omega-3s, including DHA+EPA, and short-chain ALA, which were incorporated into blood lipids, including red blood cells.  The mid and high doses studied significantly improved levels of omega-3, as measured by the OmegaScoreTM and the Omega-3 Index, leading to reduced cardiovascular and cognitive risks.  A white paper detailing these findings will be featured in Natural Products Insider and available in its entirety at NutriterraOmega3.com.

Nutriterra® is the world’s first land-based source of total omega-3 nutrients, produced by Nuseed to deliver the benefits of microalgae via its proprietary Omega-3 Canola. Nutriterra® offers a much-needed alternative to marine omega-3s to bridge the gap between growing consumer demand and finite ocean resources.   

“The growing demand for plant-based omega-3 nutrients goes well beyond the vegetarian market. Consumers are seeking better tasting options, and Nutriterra® provides a milder sensory experience than marine oils.  Consumers are also deeply concerned about ocean health. Nuseed’s sophisticated technology has the potential to double the world’s supply of DHA without depleting ocean resources,” says Benita Boettner, Nuseed Nutritional General Manager.

Nuseed partnered with Nutrasource in Canada to design and conduct a 16-week randomized, double-blind, placebo-controlled clinical trial. Healthy adult subjects consumed one of three doses of the product, or a placebo, for a period of 16 weeks.  Here are some of the key findings:

  • Nutriterra® exhibited a good safety and tolerability profile
  • Omega-3 DHA, EPA and ALA from Nutriterra® is absorbed readily and incorporated into blood lipids
  • Nutriterra® significantly improved levels of omega-3, as measured by the OmegaScoreTM and the Omega-3 Index, leading to reduced risk of:
    • all-cause mortality
    • total cardiovascular events
    • cognitive deterioration associated with aging

In addition to these findings, the white paper highlights Nuseed’s innovation in developing this technology and the positive environmental impact it delivers. By producing a plant-based source of long-chain omega-3 fatty acids, Nutriterra® reduces pressure on marine resources to supply these essential nutrients.

More about Nutriterra

 



More news from: Nuseed Pty. Ltd.


Website: http://www.nuseed.com

Published: March 3, 2021

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section


Copyright @ 1992-2024 SeedQuest - All rights reserved